BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance

Cancer Research

Volumn 75, Issue 4, 2015, Pages 732-741

  Jaspers, Janneke E ^a   Sol, Wendy ^a   Kersbergen, Ariena ^a   Schlicker, Andreas ^a   Guyader, Charlotte ^a   Xu, Guotai ^a   Wessels, Lodewyk ^a   Borst, Piet ^a   Jonkers, Jos ^a   Rottenberg, Sven ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 2461; BRCA2 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PROTEIN P53; TARIQUIDAR; TOPOTECAN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ABCB1B PROTEIN, MOUSE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ABCB1A GENE; ABCB1B GENE; ABCG2 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRCA2 GENE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOSARCOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG SENSITIZATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MESENCHYMAL CARCINOSARCOMA; MESENCHYME CELL; MONOTHERAPY; MORPHOLOGY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TRANSGENIC MOUSE; TRP53 GENE; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DEFICIENCY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MAMMARY NEOPLASMS, ANIMAL; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BRCA2 PROTEIN; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; P-GLYCOPROTEINS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84923119094     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0839     Document Type: Article

References (52)

1. Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2012;2:120066.
2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
3. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008;105:9053-8.
4. Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms, and clinical impact. Cancer Treat Rev 2012;38:689-97.
5. Huang S,H ölzel M, Knijnenburg T, Schlicker A, Roepman P,McDermottU, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF- β receptor signaling. Cell 2012;151:937-50.
6. Geyer FC, Weigelt B, Natrajan R, Lambros MBK, de Biase D, Vatcheva R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010;220:562-73.
7. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basallike breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009;117:273-80.
8. Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, et al. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol 2013;26:485-95.
9. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
10. Jonkers J, Meuwissen R, van der GuldenH, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25.
11. Gillet J-P, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013;105:452-8.
12. Hay T,Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AOH, et al. Poly (ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009;69:3850-5.
13. Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, et al. A high-throughput pharmaceutical screen identi fies compounds with specific toxicity against BRCA2-de ficient tumors. Clin Cancer Res 2010;16: 99-108.
14. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PWB, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008;14:3916-25.
15. De Plater L, Laugé A, Guyader C, Poupon M-F, Assayag F, de Cremoux P, et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 2010;103:1192-200.
16. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 2011;17:783-91.
17. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MBE, Bartels CCM, et al. Sensitivity to fi rst-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27:3764-71.
18. Lips EH, Mulder L,Hannemann J, Laddach N, Vrancken Peeters MTFD, van de Vijver MJ, et al. Indicators of homologous recombination deficiency in breast cancer and associationwith response to neoadjuvant chemotherapy. Ann Oncol 2011;22:870-6.
19. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-ofconcept trial. Lancet 2010;376:235-44.
20. Rottenberg S, Nygren AOH, Pajic M, van Leeuwen FWB, van der Heijden I, van de Wetering K, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007;104:12117-22.
21. Jonkers J, Meuwissen R, van der GuldenH, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25.
22. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013;3:68-81.
23. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinforma Oxf Engl 2004;20:307-15.
24. Kinsella RJ, Kähäri A, Haider S, Zamora J, Proctor G, Spudich G, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database 2011;2011:bar030.
25. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
26. Zhu M, Yi M, Kim CH, Deng C, Li Y, Medina D, et al. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol 2011;12:R77.
27. Hennessy BT, Gonzalez-Angulo A-M, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee J-S, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009;69:4116-24.
28. Holstege H, van Beers E, Velds A, Liu X, Joosse SA, Klarenbeek S, et al.Crossspecies comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer 2010;10:455.
29. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligationdependent probe amplification. Nucleic Acids Res 2002;30:e57.
30. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, Zander SAL, et al. High sensitivity of BRCA1-defi cient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-84.
31. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014;134:552-62.
32. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61.
33. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 1994;48:1528-30.
34. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5: 219-34.
35. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, et al. Overexpression of the BCRP/MXR/ ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63.
36. Derksen PWB, Braumuller TM, van der Burg E, Hornsveld M, Mesman E, Wesseling J, et al. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech 2011;4:347-58.
37. Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 inmice leads tometastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49.
38. Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, et al. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficientmammary tumors. Cancer Res 2012;72:2350-61.
39. Li Q-Q, Xu J-D,WangW-J, Cao X-X, ChenQ, Tang F, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009;15:2657-65.
40. SaxenaM, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011;2:e179.
41. Li W, Liu C, Tang Y, Li H, Zhou F, Lv S. Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells. Asian Pac J Cancer Prev 2011;12:2575-80.
42. Chen W-J, Wang H, Tang Y, Liu C-L, Li H-L, Li W-T. Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein. Chin J Cancer 2010;29:151-7.
43. Zander SAL, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, et al. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010;70:1700-10.
44. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012;15:50-61.
45. Faneyte IF, Kristel PM, van de Vijver MJ. Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 2001;93:114-22.
46. Huff LM, Lee J-S, Robey RW, Fojo T. Characterization of gene rearrangements leading to activation of MDR-1. J Biol Chem 2006;281:36501-9.
47. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Druginduced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013;4:1908.
48. Jung S-Y, Kim HY, Nam B-H, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 2010;120:627-37.
49. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010;101:293-9.
50. Moody SE, Perez D, Pan T, Sarkisian CJ, Portocarrero CP, Sterner CJ, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005;8:197-209.
51. Van Nes JGH, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 2012; 133:49-59.
52. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, et al. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensi fied carboplatin-based chemotherapy. Breast Cancer Res 2014;16:R47